Form 4: Beta Bionics Director Dearen Receives RSU Grant
Insider Transaction Report
Beta Bionics Director Danny L. Dearen was granted 3,997 restricted stock units under the company's 2025 Equity Incentive Plan.
Summary
- Danny L. Dearen, a Director of Beta Bionics, Inc. (BBNX), acquired 3,997 shares of common stock.
- The transaction occurred on January 13, 2026.
- The shares were acquired as a restricted stock unit (RSU) award, with an acquisition price of $0 per share.
- The RSU award was granted under the Issuer's 2025 Equity Incentive Plan.
- Following this transaction, Danny L. Dearen beneficially owns a total of 15,244 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as it indicates alignment of a director's interests with shareholders through equity ownership, which is generally viewed favorably. However, it is a routine compensation event and not a significant market driver.
Positives
- The grant of restricted stock units to a director aligns management's interests with those of shareholders, encouraging long-term value creation.
Future Outlook
The filing does not contain specific forward-looking statements or guidance beyond the details of the equity grant.
Industry Context
Equity grants, such as restricted stock units, are a standard component of executive and director compensation packages across various industries, particularly in growth-oriented technology and biotech companies like Beta Bionics. They serve to attract and retain talent while aligning insider incentives with shareholder returns.
Comparison to Industry Standards
- The granting of restricted stock units (RSUs) to directors is a common practice in the biotechnology and medical device sectors, similar to companies like Insulet Corporation (PODD) or Dexcom, Inc. (DXCM), which frequently use equity-based compensation to incentivize leadership.
- The $0 acquisition price for RSUs is standard, as these awards typically vest over time and represent a future ownership stake rather than an immediate purchase.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Utilization | The restricted stock unit award was granted under the Issuer's 2025 Equity Incentive Plan, indicating the company's ongoing use of equity-based compensation as part of its governance and incentive structure. | 01/13/2026 | Reinforces the company's commitment to aligning director and executive incentives with long-term shareholder value through established governance mechanisms. |
Stakeholder Impact
- Shareholders: Increased alignment of a director's financial interests with long-term shareholder value.
Key Dates
| Date | Description |
|---|---|
| 01/13/2026 | Date of transaction where 3,997 restricted stock units were acquired. |
| 01/14/2026 | Date the Form 4 was signed by Stephen Feider, Attorney-in-Fact for Danny L. Dearen. |
Keywords
Beta Bionics, BBNX, Danny L. Dearen, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, Director Compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.